Overview
Wearable medical robotics firm's Q4 revenue fell 6% yr/yr due to lower ASP
Company achieved record 241 MyoPro authorizations and orders in Q4
Introduces 2026 revenue guidance of $43 mln to $46 mln
Outlook
Myomo expects 2026 revenue between $43 mln and $46 mln
Company anticipates Q1 2026 revenue of $9 mln to $9.5 mln
Myomo aims to cut negative free cash flow by half in 2026
Result Drivers
RECURRING REVENUE - Recurring patient sources accounted for 42% of Q4 revenue, up from 26% in the prior year, driven by U.S. and International O&P providers and MyoConnect referrals
MARKETING STRATEGY - New marketing strategy with a focus on social media and direct-to-patient advertising launched to support MyoConnect and O&P efforts
GROSS MARGIN DECLINE - Gross margin declined to 68.6% in Q4 from 71.4% a year ago, due to lower ASP, unfavorable inventory overhead changes, and higher warranty costs
Company press release: ID:nBw262H1sa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | $11.40 mln | ||
Q4 EPS | -$0.09 | ||
Q4 Net Income | -$3.80 mln | ||
Q4 Adjusted EBITDA | -$1.90 mln | ||
Q4 Gross Margin | 68.60% | ||
Q4 Operating Expenses | $10.60 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments